The FDA must maintain a delicate balance: being a model of openness regarding the scientific basis of its decisions, while safeguarding the proprietary secrets of the industries it regulates as well as personal data.
Similar Posts
Primal Herbs Volume may be harmful due to hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Primal Herbs Volume, a product promoted and sold for sexual enhancement on various websites, including primalherbs.com, and possibly in some retail stores.Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units
Olympus is removing certain High Flow Insufflation Unit models due to software issues that may lead to overpressure events.Dr. Reddy’s Laboratories Limited | 12/12/2025 | 483
Dr. Reddy’s Laboratories Limited | 12/12/2025 | 483FDA Clinical Trials Training Modules
This training represents regulatory intelligence that sets global standards for clinical research. The content reflects current FDA thinking, emerging guidance, and real-world regulatory experience, providing participants with the most reliable and up-to-date information available.Tri-Union Seafoods Identifies Additional Quantities of Recalled Genova® Tuna at Limited Retailers Due to Inadvertent Distribution of Previously Recalled Product
El Segundo, CA, January 16, 2026 – Tri-Union Seafoods is cautioning consumers that a third-party distributor inadvertently released quarantined product that was associated to a February 2025 recall. The initial voluntary recall was conducted following notification from our supplier that the “easy opGDUFA IV: Fiscal Years 2028 – 2032
Information related to FDA’s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.